ImmunoGen Announces Webcast of Presentation at Upcoming Canaccord Genuity Virtual Growth Conference

ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming 40th Annual Canaccord Genuity Virtual Growth Conference.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, July 29, 2020
Information
Tags: 
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Clinical medicine, Medical specialties, Cancer treatments, Immunology, ImmunoGen, Antineoplastic drugs, Antibody-drug conjugate, Genuity, ImmunoGen, Monoclonal antibodies, Antibody-drug conjugates
Geotags: 
Massachusetts, United States
⚠generated by AI ↴
Summary
Key Points: 
  • ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming 40th Annual Canaccord Genuity Virtual Growth Conference.
  • The presentation is scheduled for August 12, 2020 at 9:00am ET.
  • A webcast of the presentation will be accessible through the Investors and Media section of the Company's website on www.immunogen.com .
  • ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients.


ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming 40th Annual Canaccord Genuity Virtual Growth Conference. The presentation is scheduled for August 12, 2020 at 9:00am ET.

A webcast of the presentation will be accessible through the Investors and Media section of the Company's website on www.immunogen.com. Following the live webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

Copyright: 
Copyright Business Wire 2020